PATENT CLAIM ANALYSIS

Application Number: 15873079
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "450000"]

Abstract:
Docetaxel and doxorubicin can be formulated in liposomal pharmaceutical compositions. In various embodiments, the pharmaceutical compositions include (i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol or a cholesterol derivative, DC-cholesterol, a cationic lipid, and preferably a pegylated phospholipid, and a first active pharmaceutical ingredient (API) comprising docetaxel in the first lipid layer; and (ii) a second liposome type comprising a second lipid layer, an aqueous interior, and a second API comprising doxorubicin crystallized in the aqueous interior, (iii) where the first liposome type does not comprise doxorubicin and the second liposome type does not comprise docetaxel. The pharmaceutical composition can be used to treat a subject, for example, a human subject having cancer. The cancer can be, for example, a lung cancer, preferably non-small cell lung cancer (NSCLC), colon cancer, breast cancer, or liver cancer, preferably hepatocellular carcinoma (HCC).

Claim (Index 20):
A method of making the pharmaceutical composition of  claim 1 , comprising:\n (i) making a first liposome type by concurrently introducing a first lipid solution comprising an unsaturated phospholipid, a cationic lipid, and docetaxel in ethanol through a first or plural inlet ports into a mixing chamber of a manifold and introducing a first aqueous solution through a second or plural inlet ports into the mixing chamber of the manifold, and the liposomes exit the mixing chamber through one or plural outlet chambers of the manifold, wherein the resulting first liposome type does not comprise doxorubicin; (ii) making a second liposome type by concurrently introducing a second lipid solution in ethanol through a first or plural inlet ports into a mixing chamber of a manifold and introducing a first aqueous solution through a second or plural inlet ports into the mixing chamber of the manifold, and the liposomes exit the mixing chamber through one or plural outlet chambers of the manifold, and incubating the resulting liposomes with doxorubicin, wherein the resulting second liposome type does not comprise docetaxel; and (iii) combining predetermined amounts of the first liposome type and the second liposome type, thereby making the pharmaceutical composition of  claim 1 .

Metadata:
- Claim Count in Document: 44.0
- Percentile: 86.0
- Lexical Diversity: 2.47945
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15059972', '15221832', '14208297', '14765620', '15320903']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6934503088063825
- 35 USC 102 Novelty (BERT): 0.6889402892582577
- Combined Prediction Score: 0.69299930685157
- Mean Citation Score: 417.138628
- Max Citation Score: 701.6162
- Similarity Product: 681.7812129530549

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test